Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease

Chang Qu; Qing-Qing Xu; Wen Yang; Mei Zhong; Qiuju Yuan; Yan-Fang Xian; Zhi-Xiu Lin

doi:10.1016/j.jpha.2023.07.014

Volume 13 Issue 12

Dec. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2023 > 13(12): 1526-1547

Chang Qu, Qing-Qing Xu, Wen Yang, Mei Zhong, Qiuju Yuan, Yan-Fang Xian, Zhi-Xiu Lin. Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease[J]. Journal of Pharmaceutical Analysis, 2023, 13(12): 1526-1547. doi: 10.1016/j.jpha.2023.07.014

Citation:

Chang Qu, Qing-Qing Xu, Wen Yang, Mei Zhong, Qiuju Yuan, Yan-Fang Xian, Zhi-Xiu Lin. Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease[J]. Journal of Pharmaceutical Analysis, 2023, 13(12): 1526-1547. doi: 10.1016/j.jpha.2023.07.014

Citation:

Chang Qu, Qing-Qing Xu, Wen Yang, Mei Zhong, Qiuju Yuan, Yan-Fang Xian, Zhi-Xiu Lin. Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease[J]. Journal of Pharmaceutical Analysis, 2023, 13(12): 1526-1547. doi: 10.1016/j.jpha.2023.07.014

PDF( 10364 KB)

Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease

doi: 10.1016/j.jpha.2023.07.014

Chang Qu^a,b,
Qing-Qing Xu^a,
Wen Yang^a,
Mei Zhong^a,
Qiuju Yuan^c,
Yan-Fang Xian^{a
,
,},
Zhi-Xiu Lin^{a,d
,
,}

a. School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China;
b. College of Forestry and Landscape Architecture, South China Agricultural University, Guangzhou, 510640, China;
c. Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong Science Park, Shatin, N.T., Hong Kong, China;
d. Hong Kong Institute of Integrative Medicine, The Chinese University of Hong Kong, Hong Kong, China

Funds:

This work was partially supported by National Natural Science Foundation of China (Project No.: 82104414), Natural Science Foundation of Guangdong Province of China (Project No.: 2022A1515011682) and a direct grant from The Chinese University of Hong Kong (Project No.: 2021.071).

Received Date: Mar. 26, 2023
Accepted Date: Jul. 25, 2023
Rev Recd Date: Jul. 22, 2023
Publish Date: Jul. 28, 2023

Abstract

Abstract

Gut dysbiosis, a well-known risk factor to triggers the progression of Alzheimer's disease (AD), is strongly associated with metabolic disturbance. Trimethylamine N-oxide (TMAO), produced in the dietary choline metabolism, has been found to accelerate neurodegeneration in AD pathology. In this study, the cognitive function and gut microbiota of TgCRND8 (Tg) mice of different ages were evaluated by Morris water maze task (MWMT) and 16S rRNA sequencing, respectively. Young pseudo germ-free (PGF) Tg mice that received faecal microbiota transplants from aged Tg mice and wild-type (WT) mice were selected to determine the role of the gut microbiota in the process of neuropathology. Excessive choline treatment for Tg mice was used to investigate the role of abnormal choline metabolism on the cognitive functions. Our results showed that gut dysbiosis, neuroinflammation response, Aβ deposition, tau hyperphosphorylation, TMAO overproduction and cyclin-dependent kinase 5 (CDK5)/transcription 3 (STAT3) activation occurred in Tg mice age-dependently. Disordered microbiota of aged Tg mice accelerated AD pathology in young Tg mice, with the activation of CDK5/STAT3 signaling in the brains. On the contrary, faecal microbiota transplantation from WT mice alleviated the cognitive deficits, attenuated neuroinflammation, Aβ deposition, tau hyperphosphorylation, TMAO overproduction and suppressed CDK5/STAT3 pathway activation in Tg mice. Moreover, excessive choline treatment was also shown to aggravate the cognitive deficits, Aβ deposition, neuroinflammation and CDK5/STAT3 pathway activation. These findings provide a novel insight into the interaction between gut dysbiosis and AD progression, clarifying the important roles of gut microbiota-derived substances such as TMAO in AD neuropathology.
- Alzheimer's disease,
- Gut dysbiosis,
- Neuropathology,
- TgCRND8 mice

FullText(HTML)

References(45)

References

[1]	H.W. Querfurth, F.M. LaFerla, Alzheimer’s disease, N Engl J. Med. 362 (2010) 329-344.
[2]	T.D. McKee, R.M. Loureiro, J.A. Dumin, et al., An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates, J. Neurosci. Meth. 213 (2013) 14-21.
[3]	S. Liu, C. Wang, T. Jiang, et al., The role of Cdk5 in Alzheimer’s disease, Mol. Neurobiol. 53 (2016) 4328-4342.
[4]	T. Lu, C. Wan, W. Yang, et al., Role of Cdk5 in amyloid-beta pathology of Alzheimer’s disease, Curr. Alzheimer Res. 16 (2019) 1206-1215.
[5]	Y. Wen, E. Planel, M. Herman, et al., Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing, J. Neurosci. 28 (2008) 2624-2632.
[6]	A.K. Fu, W.Y. Fu, A.K. Ng, et al., Cyclin-dependent kinase 5 phosphorylates signal transducer and activator of transcription 3 and regulates its transcriptional activity, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 6728-6733.
[7]	J. Wan, A.K. Fu, F.C. Ip, et al., Tyk2/STAT3 signaling mediates beta-amyloid-induced neuronal cell death: Implications in Alzheimer’s disease, J. Neurosci. 30 (2010) 6873-6881.
[8]	X. Hu, T. Wang, F. Jin, Alzheimer’s disease and gut microbiota, Sci. China Life Sci. 59 (2016) 1006-1023.
[9]	N.M. Vogt, R.L. Kerby, K.A. Dill-McFarland, et al., Gut microbiome alterations in Alzheimer’s disease, Sci. Rep. 7 (2017), 13537.
[10]	P. Tognini, Gut microbiota: A potential regulator of neurodevelopment, Front. Cell. Neurosci. 11 (2017), 25.
[11]	Q.-Q. Xu, W. Yang, M. Zhong, et al., Animal models of Alzheimer’s disease: Preclinical insights and challenges. Acta Mater. Med. 2 (2023) 192-215.
[12]	H. Li, S.P. Ip, Q. Yuan, et al., Isorhynchophylline ameliorates cognitive impairment via modulating amyloid pathology, tau hyperphosphorylation and neuroinflammation: Studies in a transgenic mouse model of Alzheimer’s disease, Brain Behav. Immun. 82 (2019) 264-278.
[13]	C. Qu, Q. Li, Z. Su, et al., Nano-Honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer’s disease via inhibiting neuropathology and modulating gut microbiota, J. Adv. Res. 35 (2022) 231-243.
[14]	Q. Xu, Z. Su, W. Yang, et al., Patchouli alcohol attenuates the cognitive deficits in a transgenic mouse model of Alzheimer’s disease via modulating neuropathology and gut microbiota through suppressing C/EBPβ/AEP pathway, J. Neuroinflammation 20 (2023), 19.
[15]	L. Zhao, Y. Huang, L. Lu, et al., Saturated long-chain fatty acid-producing bacteria contribute to enhanced colonic motility in rats, Microbiome 6 (2018), 107.
[16]	Q. Wang, Y. Shen, X. Wang, et al., Concomitant memantine and Lactobacillus plantarum treatment attenuates cognitive impairments in APP/PS1 mice, Aging 12 (2020) 628-649.
[17]	Y. Xian, S.P. Ip, H. Li, et al., Isorhynchophylline exerts antidepressant-like effects in mice via modulating neuroinflammation and neurotrophins: Involvement of the PI3K/Akt/GSK-3β signaling pathway, FASEB J. 33 (2019) 10393-10408.
[18]	Y. Xian, D. Fan, S.P. Ip, et al., Antidepressant-like effect of isorhynchophylline in mice, Neurochem. Res. 42 (2017) 678-685.
[19]	J.C. Cruz, H.C. Tseng, J.A. Goldman, et al., Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles, Neuron 40 (2003) 471-483.
[20]	C. Chen, E.H. Ahn, S.S. Kang, et al., Gut dysbiosis contributes to amyloid pathology, associated with C/EBPβ/AEP signaling activation in Alzheimer’s disease mouse model, Sci. Adv. 6 (2020), eaba0466.
[21]	P. Liu, G. Peng, N. Zhang, et al., Crosstalk between the gut microbiota and the brain: An update on neuroimaging findings, Front. Neurol. 10 (2019), 883.
[22]	W. Chen, X. Zhang, W. Huang, Role of neuroinflammation in neurodegenerative diseases (review), Mol. Med. Rep. 13 (2016) 3391-3396.
[23]	I. Morales, L. Guzman-Martinez, C. Cerda-Troncoso, et al., Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches, Front. Cell. Neurosci. 8 (2014), 112.
[24]	J.W. Kinney, S.M. Bemiller, A.S. Murtishaw, et al., Inflammation as a central mechanism in Alzheimer’s disease, Alzheimers Dement. 4 (2018) 575-590.
[25]	H.C. Brigas, M. Ribeiro, J.E. Coelho, et al., IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer’s disease, Cell Rep. 36 (2021), 109574.
[26]	H. Akiyama, S. Barger, S. Barnum, et al., Inflammation and Alzheimer’s disease, Neurobiol. Aging 21 (2000) 383-421.
[27]	F. Pistollato, S.S. Cano, I. Elio, et al., Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease, Nutr. Rev. 74 (2016) 624-634.
[28]	S. Liu, J. Gao, M. Zhu, et al., Gut microbiota and dysbiosis in Alzheimer’s disease: Implications for pathogenesis and treatment, Mol. Neurobiol. 57 (2020) 5026-5043.
[29]	T. Doifode, V.V. Giridharan, J.S. Generoso, et al., The impact of the microbiota-gut-brain axis on Alzheimer’s disease pathophysiology, Pharmacol. Res. 164 (2021), 105314.
[30]	S. Westfall, D.M. Dinh, G.M. Pasinetti, Investigation of potential brain microbiome in Alzheimer’s disease: Implications of study bias, J. Alzheimers Dis. 75 (2020) 559-570.
[31]	J.F. Cryan, K.J. O'Riordan, C.S.M. Cowan, et al., The microbiota-gut-brain axis, Physiol. Rev. 99 (2019) 1877-2013.
[32]	S. Isaiah, D.T. Loots, R. Solomons, et al., Overview of brain-to-gut axis exposed to chronic CNS bacterial infection(s) and a predictive urinary metabolic profile of a brain infected by Mycobacterium tuberculosis, Front. Neurosci. 14 (2020), 296.
[33]	Z. Wang, E. Klipfell, B.J. Bennett, et al., Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease, Nature 472 (2011) 57-63.
[34]	C. Roncal, E. Martinez-Aguilar, J. Orbe, et al., Trimethylamine-N-oxide (TMAO) predicts cardiovascular mortality in peripheral artery disease, Sci. Rep. 9 (2019), 15580.
[35]	M. Dambrova, G. Latkovskis, J. Kuka, et al., Diabetes is associated with higher trimethylamine N-oxide plasma levels, and 124 (2016) 251-256.
[36]	C.W.H. Chan, B.M.H. Law, M.M.Y. Waye, et al., Trimethylamine-N-oxide as one hypothetical link for the relationship between intestinal microbiota and cancer - where we are and where shall we go? J. Cancer 10 (2019) 5874-5882.
[37]	R. Xu, Q. Wang, Towards understanding brain-gut-microbiome connections in Alzheimer’s disease, BMC Syst. Biol. 10 Suppl 3 (2016), 63.
[38]	Q. Ma, C. Xing, W. Long, et al., Impact of microbiota on central nervous system and neurological diseases: The gut-brain axis, J. Neuroinflammation 16 (2019), 53.
[39]	D. Li, Y. Ke, R. Zhan, et al., Trimethylamine-N-oxide promotes brain aging and cognitive impairment in mice, Aging Cell 17 (2018), e12768.
[40]	N.M. Vogt, K.A. Romano, B.F. Darst, et al., The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease, Alzheimers. Res. Ther. 10 (2018), 124.
[41]	Food and Nutrition Board, Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Panthotenic Acid, Biotin, and Cholin, National Academy Press, Washington, 1998.
[42]	S.C. Garner, M.H. Mar, S.H. Zeisel, Choline distribution and metabolism in pregnant rats and fetuses are influenced by the choline content of the maternal diet, J. Nutr. 125 (1995) 2851-2858.
[43]	S.H. Zeisel, K.A. da Costa, P.D. Franklin, et al., Choline, an essential nutrient for humans, FASEB J. 5 (1991) 2093-2098.
[44]	K.A. da Costa, M. Badea, L.M. Fischer, et al., Elevated serum creatine phosphokinase in choline-deficient humans: Mechanistic studies in C2C12 mouse myoblasts, Am. J. Clin. Nutr. 80 (2004) 163-170.
[45]	K.A. da Costa, M.D. Niculescu, C.N. Craciunescu, et al., Choline deficiency increases lymphocyte apoptosis and DNA damage in humans, Am. J. Clin. Nutr. 84 (2006) 88-94.